Navigation Links
Octapharma Accepting Applications for Research Grants Through March 31
Date:2/4/2010

LACHEN, Switzerland and HOBOKEN, N.J., Feb. 4 /PRNewswire/ -- Octapharma USA will accept applications until March 31 for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in April.

Octapharma AG, one of the largest plasma products manufacturers in the world, launched the grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"The grants program has been very well-received and we expect to be announcing our first recipient shortly," said Octapharma USA President Flemming Nielsen. "The U.S. market is very important to Octapharma and the grants program is just one way that we demonstrate our commitment. Our vision of providing patients with the safest, highest quality products available is stronger than ever."

Grant applications are accepted online only at www.octapharmagrants.com.  All grant requests will be evaluated by the Octapharma Grants Committee in April and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD) and granted orphan drug exclusivity. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

SOURCE Octapharma USA

RELATED LINKS
http://www.octapharma.com/USA/?&agree=yes

'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
2. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
3. CCMC Accepting Applications for Voluntary Service on its Board of Commissioners
4. Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery
5. Sleep HealthCenters Now Accepting Students for A-STEP Sleep Technologist Program
6. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. ASTRO Accepting Survivor Circle Grant Applications
9. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
10. CCMC Accepting Applications for Second Annual Patricia McCollom Scholarship Through Aug. 1
11. Pittsburgh Day Spa Welcomes Dermatologist, Ana C. Busquets, MD, FAAD And Is Accepting New Patients In Upper St. Clair And Cranberry Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: